The identification of risk factors for lower extremity musculoskeletal (MSK) injury in sport is required to inform primary and secondary injury prevention strategies.Objective
To determine whether measures of poor movement quality are associated with lower extremity MSK injury in sport.Design
Five electronic databases (Medline, EMBASE, CINAHL, Sport Discus, SCOPUS) were systematically searched using keywords and Medical Sub-heading terms. Studies selected included: English language; original data; prospective analytic design; a rating of movement compensation, asymmetry, impairment or efficiency through composite batteries and/or individual tests; and participants with lower extremity MSK injury sustained with sport participation. PRISMA guidelines were followed and two independent raters assessed study quality [Downs and Black (DB) criteria] and level of evidence (Oxford Centre of Evidence-Based Medicine model).Results
Of 4361 potential relevant studies, 13 were included. The majority (11/13) of the studies were low quality cohort studies (level 4 evidence). Median DB score was 11/33 (range 3–14). Heterogeneity in methodology and injury definition precluded meta-analyses. The Functional Movement Screen (FMS) was the most common movement quality outcome investigated (11/13 studies). Two studies considered interrelationships between risk factors, five reported diagnostic accuracy and none evaluated an intervention program targeting individuals identified as high-risk. There is inconsistent evidence that poor movement quality is associated with increased risk of lower extremity injury in sport.Conclusions
There is insufficient evidence for widespread adoption of movement quality screening programs for predicting lower-extremity injury in sport. Future research should aim to identify the most relevant movement quality outcomes for predicting injury risk through high quality cohort studies. This should be followed by development and evaluation of pre-participation screening and lower extremity injury prevention programs through high quality randomized controlled trials targeting individuals at the greatest risk based on screening tests with validated test properties.